Related Experiment Video

Updated: Aug 14, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Identification of CYP2D6 impaired functional alleles in Mexican Americans

Huai-Rong Luo1, Andrea Gaedigk, Vasileios Aloumanis

  • 1Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Mail Stop 1018, Breidenthal Building, 3901 Rainbow Blvd., Kansas City, KS 66160-7417, USA.

European Journal of Clinical Pharmacology
|November 12, 2005
PubMed
Abstract

Insights

Genetic factors significantly influence CYP2D6 activity in Mexican Americans. Specific CYP2D6 alleles, like *4, *5, *6, *9, *10, and *41, are major contributors to reduced drug metabolism, impacting treatment efficacy and safety.

Area of Science:

  • Pharmacogenomics
  • Human Genetics
  • Drug Metabolism

Background:

  • Cytochrome P450 2D6 (CYP2D6) is crucial for metabolizing numerous drugs.
  • Understanding genetic variations in CYP2D6 is vital for personalized medicine, especially in diverse populations like Mexican Americans.
  • Previous studies have not fully elucidated the genetic basis of CYP2D6 activity variability in this demographic.

Purpose of the Study:

  • To conduct an extended genotyping analysis of the CYP2D6 gene in Mexican Americans.
  • To identify specific genetic factors contributing to the variability of CYP2D6 enzyme activity within this population.

Main Methods:

  • Genotyping was performed for multiple CYP2D6 alleles (*6, *7, *8, *9, *11, *14, *29, *41, *45, *46) and the 2988G>A SNP in 264 Mexican Americans.
  • Phenotyping data from 236 subjects using dextromethorphan was utilized.
  • Associations between identified genotypes and measured CYP2D6 activity were statistically analyzed.

Main Results:

  • High frequencies of functional CYP2D6*1 and *2 alleles (73.1%) were observed.
  • Significant frequencies of non-functional CYP2D6*4 (10.0%) and reduced-function CYP2D6*41 (9.5%) alleles were detected.
  • Alleles CYP2D6*5, *6, *9, *10, and the 2988A variant were present at lower frequencies, while several alleles were absent or rare.

Conclusions:

  • Null alleles (CYP2D6*4, *5, *6) and reduced-function alleles (CYP2D6*9, *10, *41) are primary drivers of diminished dextromethorphan metabolism in Mexican Americans.
  • These genetic variations have significant implications for the safety and efficacy of drugs metabolized by CYP2D6 in this population.
  • Further research into CYP2D6 pharmacogenomics in diverse ethnic groups is warranted.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...